Loading...
Tuberculosis care has been hindered by the required minimum 6-month course of antimicrobial therapy. Now, researchers have conducted a phase 3 noninferiority trial evaluating 6 months of rifampin, isoniazid, pyrazinamide, and ethambutol (RIPE; standard therapy) compared with either of two 4-month regimens (each with 1200-mg rifapentine daily [replacing rifampin]; one regimen with and one without 400-mg moxifloxacin daily [replacing ethambutol]) with a primary efficacy outcome of tuberculosis-free survival at 12 months. Investigators randomized 2516 patients in 13 countries with pulmonary tuberculosis; 2343 participants had microbiologic confirmation of tuberculosis (including 194 with concurrent HIV infection and 1703 with cavitation) and 2…